ADORA2A and schizophrenia: Our findings support the idea that A2ARs may perhaps serve as a biomarker of cognitive deficits in schizophrenia, and future investigations are necessary to understand whether modulating A2AR activity may offer an efficacious therapeutic avenue for addressing cognitive decline.